Strides receives FDA OK for adenosine and meloxicam
This article was originally published in Scrip
Executive Summary
Strides Arcolab has received US FDA approval for its ANDA for adenosine injection 3mg/ml, packaged in 6mg/2ml single dose vials, and meloxicam tablets 7.5mg and 15mg. Adenosine injection, a cardiovascular agent, is a generic version of Astellas Pharma's Adenocard, while meloxicam tablets are a generic version of Boehringer Ingelheim's non-steroidal anti-inflammatory drug, Mobic. Strides now has approval for 16 sterile and 12 oral products.